Lilliana Trinch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lilliana Trinch has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Adam H. Courtney
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA
1 shared publication - Claire Shudde
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA
1 shared publication - Dana King
BRCF Bioinformatics Core, University of Michigan
1 shared publication - Grace A. Aleck
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA
1 shared publication - Jiajia Zhou
Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA
1 shared publication - Monica K. Chanda
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA
1 shared publication
Latest Publications
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (107) , eadn9633
An engineered viral protein activates STAT5 to prevent T cell suppression
T cell therapy efficacy can be compromised if cytokine-induced Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling is dysregulated or insufficient to sustain functionality. Here, we demonstrate that LCK kinase activity can be recruited to noncanonical protein substrates to directly activate targeted STAT proteins in T cells. STAT activation was accomplished by engineering the herpesvirus saimiri tyrosine kinase interacting protein (TIP) to provide a platform for the enforced recruitment of LCK to STAT proteins. We determined that a minimal region of TIP that binds to LCK could be combined with STAT binding sites derived from endogenous cytokine receptors. These constructs activated targeted STAT proteins in a cytokine-independent manner. We identified a STAT5 activator that sustained CD8+ T cell survival and cytotoxic function ex vivo in the absence of interleukin-2. Tumor outgrowth was reduced in vivo because of enhanced T cell persistence and functionality. Single-cell transcriptomics revealed that the STAT5 activator prevented the expression of genes associated with an exhausted T cell fate. Our findings demonstrate that signaling pathways can be rewired in T cells to sustain their function in solid tumors.
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (107) , eadn9633
An engineered viral protein activates STAT5 to prevent T cell suppression
T cell therapy efficacy can be compromised if cytokine-induced Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling is dysregulated or insufficient to sustain functionality. Here, we demonstrate that LCK kinase activity can be recruited to noncanonical protein substrates to directly activate targeted STAT proteins in T cells. STAT activation was accomplished by engineering the herpesvirus saimiri tyrosine kinase interacting protein (TIP) to provide a platform for the enforced recruitment of LCK to STAT proteins. We determined that a minimal region of TIP that binds to LCK could be combined with STAT binding sites derived from endogenous cytokine receptors. These constructs activated targeted STAT proteins in a cytokine-independent manner. We identified a STAT5 activator that sustained CD8+ T cell survival and cytotoxic function ex vivo in the absence of interleukin-2. Tumor outgrowth was reduced in vivo because of enhanced T cell persistence and functionality. Single-cell transcriptomics revealed that the STAT5 activator prevented the expression of genes associated with an exhausted T cell fate. Our findings demonstrate that signaling pathways can be rewired in T cells to sustain their function in solid tumors.